|
|
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date11 Apr 2005 |
A Phase 1, Dose Escalating Study of the Safety, Tolerability, and Pharmacokinetics of IL-1-Ra Topically Administered to Eyes of Healthy Adult Subjects
The purpose of this study is to assess the safety and tolerability of ocular administration of Topical Interleukin-1-Receptor Antagonist in healthy volunteers. Additionally, the PK of Interleukin-1-Receptor Antagonist will be assessed.
100 Clinical Results associated with Chengdu Rhodiola Bio-Pharmaceutical Co Ltd
0 Patents (Medical) associated with Chengdu Rhodiola Bio-Pharmaceutical Co Ltd
100 Deals associated with Chengdu Rhodiola Bio-Pharmaceutical Co Ltd
100 Translational Medicine associated with Chengdu Rhodiola Bio-Pharmaceutical Co Ltd